SCM
SYRE icon

Soleus Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Soleus Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,794
Closed -$3.42M – 74
2020
Q2 		$3.42M Sell
14,794
-6,666
-31% -$1.27M 1.95% 16
2020
Q1 		$2.5M Buy
21,460
+3,133
+17% +$533K 2.91% 13
2019
Q4 		$3.5M Buy
+18,327
New +$3.6M 3.38% 8

Other funds holding SYRE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Soleus Capital Management's SYRE Position: Q3 2020 in Review

Soleus Capital Management sold out of Spyre Therapeutics (SYRE) in Q3 2020, closing a stake of 14,794 shares — an estimated $3.42M sold.

Soleus Capital Management first reported a position in SYRE in Q4 2019 and held it in 3 quarters. The position peaked at $3.5M in Q4 2019. 94 funds tracked by Wall St. Rank hold SYRE as of Q3 2020.

  • Soleus Capital Management reported no remaining Spyre Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Soleus Capital Management sold 14,794 Spyre Therapeutics shares in Q3 2020, an estimated $3.42M.
  • Soleus Capital Management first reported a position in Spyre Therapeutics in Q4 2019 and held it in 3 quarters.
  • Soleus Capital Management's Spyre Therapeutics position peaked at $3.5M in Q4 2019.
  • 94 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2020.

Based on Soleus Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.